MichaelLGrossbardMD

PubMed

• 1 citations
  Characterization of Second Primary Malignancies in Mucosa-Associated Lymphoid Tissue Lymphomas: A SEER Database Interrogation.
  Sunita Timilsina, Aaron Damato, Nibash Budhathoki, Michael L. Grossbard, Marc Braunstein> ;Clinical Lymphoma, Myeloma & Leukemia. 2021 Aug 12
• 20 citations
  Impaired Humoral Immunity to SARS-CoV-2 Vaccination in Non-Hodgkin Lymphoma and CLL Patients
  Catherine Diefenbach, Jessica Caro, Akiko Koide, Michael L. Grossbard, Judith D. Goldberg, Bruce Raphael, Kenneth B. Hymes, Tibor Moskovits, Maxim Kreditor, David Kami...> ;Medrxiv. 2021 Jun 3
• 2 citations
  Radiation Dose Reduction in Early-Stage Hodgkin Lymphoma.
  Bhartesh A. Shah, Cheongeun Oh, S. Peter Wu, Jerome M. Karp, Michael L. Grossbard, Naamit K. Gerber> ;Clinical Lymphoma, Myeloma & Leukemia. 2020 Dec 1
• In Reply to Zhang.
  Rahul R. Parikh, Michael L. Grossbard, Louis B. Harrison, Joachim Yahalom> ;International Journal of Radiation Oncology, Biology, Physics. 2017 Oct 1
• 3 citations
  Survival of Asian Females With Advanced Lung Cancer in the Era of Tyrosine Kinase Inhibitor Therapy
  Daniel J. Becker, Juan P. Wisnivesky, Michael L. Grossbard, Abraham Chachoua, D. Ross Camidge, Benjamin Levy> ;Clinical Lung Cancer. 2017 Jan 1
• 6 citations
  Impact of delays in definitive treatment on overall survival: a National Cancer Database study of patients with Hodgkin lymphoma.
  Rahul R. Parikh, Michael L. Grossbard, Louis B. Harrison, Joachim Yahalom> ;Leukemia & Lymphoma. 2016 May 1
• 16 citations
  Association of intensity-modulated radiation therapy on overall survival for patients with Hodgkin lymphoma
  Rahul R. Parikh, Michael L. Grossbard, Louis B. Harrison, Joachim Yahalom> ;Radiotherapy and Oncology. 2016 Jan 1
• 38 citations
  Disparities in survival by insurance status in patients with Hodgkin lymphoma
  Rahul R. Parikh, Michael L. Grossbard, B. Lee Green, Louis B. Harrison, Joachim Yahalom> ;Cancer. 2015 Oct 1
• 27 citations
  Early-Stage Classic Hodgkin Lymphoma: The Utilization of Radiation Therapy and Its Impact on Overall Survival.
  Rahul R. Parikh, Michael L. Grossbard, Louis B. Harrison, Joachim Yahalom> ;International Journal of Radiation Oncology, Biology, Physics. 2015 Nov 1
• 9 citations
  Early-stage nodular lymphocyte-predominant Hodgkin lymphoma: the impact of radiotherapy on overall survival
  Rahul R. Parikh, Michael L. Grossbard, Louis B. Harrison, Joachim Yahalom> ;Leukemia & Lymphoma. 2016 Feb 1
• 25 citations
  Long-term outcomes and patterns of failure in orbital lymphoma treated with primary radiotherapy.
  Rahul R. Parikh, Bruce K. Moskowitz, Elizabeth Maher, David Della Rocca, Robert C. Della Rocca, Bruce Culliney, Ilan Shapira, Michael L. Grossbard, Louis B. Harrison, ...> ;Leukemia & Lymphoma. 2015 Jan 28
• 5 citations
  Cancer trends among the extreme elderly in the era of cancer screening.
  Daniel Becker, Shannon N. Ryemon, Jessica Gross, Benjamin Levy, Michael L. Grossbard, Ronald D. Ennis> ;Journal of Geriatric Oncology. 2014 Oct 1
• 12 citations
  Nodular Lymphocyte Predominant Hodgkin Lymphoma: Biology, Diagnosis and Treatment
  Anupama Goel, Wen Fan, Amit A. Patel, Madhuri Devabhaktuni, Michael L. Grossbard> ;Clinical Lymphoma, Myeloma & Leukemia. 2014 Aug 1
• 18 citations
  Hepatosplenic γδ T-cell lymphoma: an overview.
  Koppany Visnyei, Michael L. Grossbard, Ilan Shapira> ;Clinical Lymphoma, Myeloma & Leukemia. 2013 Aug 1
• 2 citations
  Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including ade...
  Adam J. Olszewski, Michael L. Grossbard, Michael S. Chung, Sree Bhavani Chalasani, Stephen Malamud, Tahir Mirzoyev, Peter Kozuch> ;Journal of Gastrointestinal Cancer. 2013 Jun 1
• 37 citations
  Impact of Oncology Drug Shortages on Patient Therapy: Unplanned Treatment Changes
  Daniel Becker, Sumit Talwar, Benjamin P. Levy, Molly Thorn, Janna Roitman, Ronald H. Blum, Louis B. Harrison, Michael L. Grossbard> ;Journal of Oncology Practice. 2013 Mar 19
• 80 citations
  Vitamin D and Breast Cancer
  Theresa Shao, Paula Klein, Michael L. Grossbard> ;The Oncologist. 2012 Jan 1
• 66 citations
  Breast cancer in female-to-male transsexuals: two cases with a review of physiology and management.
  Theresa Shao, Michael L. Grossbard, P Klein> ;Clinical Breast Cancer. 2011 Dec 1
• 17 citations
  A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254
  Richard R. Furman, Michael L. Grossbard, Jeffrey L. Johnson, Andrew L. Pecora, Peter A. Cassileth, Sin-Ho Jung, Bruce A. Peterson, Lee M. Nadler, Arnold S. Freedman, R...> ;Leukemia & Lymphoma. 2011 Mar 25
• 1 citations
  Extended-Duration Therapy in Advanced Non–Small-Cell Lung Cancer: Promise and Pitfalls
  Benjamin Levy, Alexander Drilon, Kar Leung Siu, Michael Grossbard> ;Clinical Lung Cancer. 2010 Nov 1
• 11 citations
  Efficacy and toxicity of chemoradiation in the treatment of HIV-associated anal cancer.
  David Hauerstock, Ronald D. Ennis, Michael L. Grossbard, Andrew Evans> ;Clinical Colorectal Cancer. 2010 Oct 1
• 5 citations
  Systemic approaches for multifocal bronchioloalveolar carcinoma: Is there an appropriate target?
  Benjamin P. Levy, Alexander Drilon, Liana Makarian, Amit A. Patel, Michael L. Grossbard> ;Oncology. 2010 Sep 15
• 25 citations
  Primary central nervous system mucosa-associated lymphoid tissue lymphoma: case report and literature review.
  Wajeeha Razaq, Anupama Goel, Ali Amin, Michael L. Grossbard> ;Clinical Lymphoma & Myeloma. 2009 Jun 1
• 1 citations
  Optimal response to 100 μg/kg anti-Rh(D) in two patients who had suboptimal responses to 75 μg/kg anti-Rh(D)†
  Mala Varma, Elizabeth J. Beautyman, Michael L. Grossbard> ;American Journal of Hematology. 2009 Feb 1
• 11 citations
  Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer.
  Peter Kozuch, Steve Malamud, Carrie Wasserman, Peter Homel, Takhir Mirzoyev, Michael L. Grossbard> ;Clinical Colorectal Cancer. 2009 Jan 1
• Join now to see all

Journal Articles

• Nodular Lymphocyte Predominant Hodgkin Lymphoma: Biology, Diagnosis and Treatment  
  Goel A, Fan W, Patel AA, Devabahktuni M, Grossbard, ML, Clin Lymphoma, Myeloma, Leuk, 1/1/2014
• Hepatosplenic T-cell lymphoma: An overview  
  Visnyei K, Grossbard ML, Shapira I, Clin Lymphoma, Myeloma, Leuk, 1/1/2013
• Phiase I study of Oxaliplatin in combination with Gemcitabine, Irinotecan, and 5-Fluorouracil/Leuconvorin (G-FLIE) in patirnts with metastatic solid tumors including a...  
  Olszewski AJ, Grossbard ML, Chung MS, Chalasani SB, Malamud S, Mirzoyev T, Kozuch PS, J Gastrointest Cancer, 1/1/2013
• Impact of oncology drug shortages on patient therapy: unplanned treatment changes  
  Becker DJ, Talwar S, Levy BP, Thorn M, Roitman J, Blum RH, Harrison LB, Grossbard ML, J Oncol Practice, 1/1/2013
• KRAS mutations predict sensitivity to pemetrexed chemotherapy  
  Levy B, Drilon A, Chachoua A, Seetaramu N, Richardson S, Lucido D, Legasto A, Grossbard M, Becker D, Lung Cancer Management, 1/1/2013
• Vitamin D and breast cancer  
  Shao T, Klein P, Grossbard ML, The Oncologist, 1/1/2012
• Extremely late extramedullary relapse of acute promyelocytic leukemia, case report and review of the literature  
  Kra J, Shapira I, Grossbard ML, J Hematol, 1/1/2012
• Environmental music therapy: A pilot study on the effects of music therapy in a chemotherapy infusion suite  
  Canga B, Hahm CL, Lucido D, Grossbard ML, Loewy JV, Music and Medicine, 1/1/2012
• Cancer Leukemia Group B; Eastern Cooperative Oncology Group A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant  
  Furman RR, Grossbard ML, Johnson JL, Pecora AL, Cassileth PA, Jung SH, Peterson BA, Nadler LM, Freedman A, Bayer RL, Bartlett NL, Hurd DD, Cheson BD, Leuk Lymphoma, 1/1/2011
• Systemic approaches for multifocal bronchioloalveolar carcinoma: Is there an appropriate target  
  Levy BP, Drilon A, Makarian L, Patel AA, Grossbard ML, Oncology, 1/1/2010
• Extended duration therapy in advanced non-small cell lung cancer: Promise and pitfalls  
  Levy B, Drilon A,, Siu K., Grossbard M, Clinical Lung Cancer, 1/1/2010
• Efficacy and toxicity of chemoradiation in the treatment of HIV-associated anal cancer  
  Hauerstock D, Ennis RD, Grossbard M, Evans A, Cinical Colerectal Cancer, 1/1/2010
• Phase II trial of Erlotinib and Capecitabine for patients with previously untreated metastatic colorectal cancer  
  Kozuch P, Malamud S, Wasserman C, Homel P, Mirzoyev T, Grossbard M, Clinical Colorectal Cancer, 1/1/2009
• Optimal response to 100 ug/kg anti-Rh (D) in two patients who had suboptinal responses to 75 ug/kg anti-RH (D)  
  Varma M, Beuatyman EJ, Grossbard ML, Am J Hematology, 1/1/2009
• Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with meta...  
  Goel A, Grossbard ML, Malamud S, Homel P, Dietrich M, Rodriguez T, Mirzoyev T, Kozuch P, Anticancer Drugs, 1/1/2007
• The horizon of antiangiogenic therapy for colorectal cancer  
  Olszewski AJ, Grossbard ML, Kozuch PS, Oncology, 1/1/2005
• Optimizimg adjuvant chemotherapy in early-stage breast cancer: The Perez/Muss article reviewed  
  Sachelarie I, Grossbard ML, Blum RH, Oncology, 1/1/2005
• Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma  
  Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Fisher RI, Leuk Lymphoma, 1/1/2005
• Bone marrow metastases from glioblastoma multifome-a case report and review of the literature  
  Rajagopalan V, El Kamar FG, Thayaparan R, Grossbard ML, J Neuro-Oncology, 1/1/2005
• Commentary: Alemtuzumab in B-cell chronic lymphocytic leukemia  
  Shapira I, Grossbard ML, Clinical Lymphoma, 1/1/2004
• Gallbladder and biliary tract carcinoma: a comprehensive update, part I  
  Rajagopalan V, Daines WP, Grossbard ML, Kozuch P, Oncology, 1/1/2004
• Gallbladder and biliary tract carcinoma: a comprehensive update, part II  
  Daines WP, Rajagopalan V, Grossbard ML, Kozuch P, Oncology, 1/1/2004
• Phase I dose-finding study of biweekly irinotecan in combination with fixed doses of 5-fluorouracil/leucovorin, gemcitabine and cisplatin (G-FLIP) in patients with adv...  
  Rachamalla R, Malmud S, Grossbard ML, Mathew S, Dietrich M, Kozuch P, Anti-Cancer Drugs, 1/1/2004
• Pancreatic carcinoma with brain metastases: case report and literature review  
  El Kamar FG, Jindal K, Grossbard ML, Mizrachi HH, Kozuch PS, Digestive and Liver Disease, 1/1/2004
• Complications of Therapy in Cancer Patients: Case 2 Scrotal Ulceration During All-Trans-Retinoic Acid Therapy for Acute Promyelocytic Leukemia  
  Gettinger S, Shapira I, Scheinfeld, Grossbard M, J Clin Oncol, 1/1/2004
• Join now to see all

Books/Book Chapters

• Clinical Practice of Hematology and Oncology: Presentation, Diagnosis and Treatment 
  Chapter: Lymphadenopathy. 
  Kozuch P, Grossbard MLEditors: Furie B, Mayer RJ, Cassileth P, Atkins M.Harcourt, Orlando2004
• Oxford Textbook of Medicine 
  Chapter: Chemotherapy and radiation therapy. 
  Page 260 - 264Grossbard ML, Chabner BAEditors: Oxford University Press.Oxford2003
• Current Topics In Microbiology and Immunology: Clinical Applications of Targeted Toxins 
  Chapter: Clinical trials with blocked ricin immunotoxins. 
  Page 35 - 56O'Toole JE, Esseltine D, Lynch TJ, Lambert JM, Grossbard MLEditors: Frankel AE.Springer-Verlag, Berlin1998
• Monoclonal Antibody Based Therapy of Cancer 
  Chapter: Immunotoxin therapy of lymphoma: Studies with Anti-B4-blocked Ricin. 
  Page 91 - 112Multani PS, Grossbard MLEditors: Grossbard ML.Marcel Dekker, New York1998
• Cancer Chemotherapy and Biological Response Modifiers Annual 17 
  Chapter: Antimetabolites. 
  Page 1 - 39Johnston PG, Takimoto CH, Grem JL, Fidias P, Grossbard ML, Chabner BA, Allegra CJ, Chu EEditors: Pinedo HM, Longo DL, Chabner BA.Elsevier Science BV, New York1997
• Biologic Therapy of Cancer 
  Chapter: Clinical applications of monoclonal antibodies in cancer: B-cell lymphoma. 
  Page 553 - 565Kwak LW, Grossbard ML, Urba WJEditors: DeVita VT Jr., Hellman S, Rosenberg SA.J.B. Lippincott, PhiladelphiaEdition 2nd,1995
• ASCO Fall Conference: Educational Book 
  Chapter: Immunotoxin therapy of cancer. 
  Page 29 - 36Grossbard ML1994
• Immunoconjugate Therapy of Hematologic Malignancies 
  Chapter: Immunotoxin therapy of lymphoma. 
  Page 111 - 131Grossbard ML, Nadler LMEditors: Rosen ST.Kluwer Academic Publishers, Norwell, MA1993
• Important Advances in Oncology 1992 
  Chapter: Immunotoxin therapy of malignancy. 
  Page 111 - 135Grossbard ML, Nadler LMEditors: DeVita VT Jr., Hellman S, Rosenberg SA.J.B. Lippincott, Philadelphia1992
• Chronic Lymphocytic Leukemia 
  Chapter: Innovative treatment strategies for CLL: Monoclonal antibodies, immunoconjugates, and bone marrow transplantation. 
  Page 337 - 367Rabinowe SN, Grossbard ML, Nadler LMEditors: Cheson BD.Marcel Dekker Publishers, New York1992
• Autologous Bone Marrow Transplantation: Proceedings of the Fifth International Symposium 
  Chapter: Immunotherapy with Anti-B4 blocked Ricin for B-cell leukemias and lymphomas: Implications for the post-ABMT patient. 
  Page 763 - 770Grossbard ML, Breitmeyer J, Coral F, Schlossman SF, Nadler LMEditors: Dicke KA, Armitage JO, and Dicke-Evinger MJ.University of Nebraska Medical Center, Omaha1991
• Join now to see all

Abstracts/Posters

• Evaluation of the Functional Landscape of Systemic Immunity in Classical Hodgkin Using a Novel Single Cell Platform (Isolight)
  Michael L. Grossbard, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• KRAS mutations and outcomes for patients with stage IV NSCLC treated with frontline platinum/pemetrexed based chemotherapy.
  Levy B, Seetharamu N, Richardson S, Becker DJ, Choi W, Evans A, Bhora FY, Connery CP, Grossbard ML, Chachoua A, J Clin Oncol, 1/1/2012
• Impact of oncology drug shortages on patient treatment.
  Becker DJ, Talwar S, Levy B, Thorn M, Roitman J, Blum RH, Harrison LB, Grossbard ML, J Clin Oncol, 1/1/2012

Lectures

• Medical Grand Rounds: "Indolent Lymphoma: Concept to a Cure" 
  New York University - 1/1/2014
• "Frequently Asked Questions in Lymphoma" Panel Discussion 
  New York - 1/1/2013
• Grand Rounds: "Indolent Lymphoma: New Therapy Paradigms" 
  Yale Cancer Center-, New Haven, CT - 1/1/2013
• Hematology/Oncology Grand Rounds: "Importance of Dose Intensity in the Therapy of NHL" 
  Newark Beth Israel Medical Center - 1/1/2010
• Medical Grand Rounds: "CPC-Burkitt's NHL of Kidney" 
  St. Luke's-Roosevelt Hospital - 1/1/2010
• "Importance of Dose Intensity in the Therapy of NHL" 
  Metropolitan Hospital, NY - 1/1/2009
• "CLL: Update 2007" 
  Metropolitan Hospital, NY - 1/1/2007
• Medical Grand Rounds: "CLL: Update 2007" 
  St. Luke's-Roosevelt Hospital Center - 1/1/2007
• Hematology/Oncology Grand Rounds: "New Therapy Options in Aggressive NHL" 
  Mt. Sinai Medical Center, NY - 1/1/2005
• Medical Grand Rounds: "Update on Aggressive NHL" 
  St. Luke's-Roosevelt Hospital Center - 1/1/2004
• Grand Rounds: "Aggressive NHL" 
  St. Vincent's Hospital-Staten Island, NY - 1/1/2004
• Hematology/Oncology Grand Rounds: "Monoclonal Antibody Therapy of Indolent Lymphoma" 
  Thomas Jefferson Medical Center, Philadelphia - 1/1/2003
• Hematology Grand Rounds: "Monoclonal Antibody Therapy of Follicular Lymphoma" 
  University of Vermont - 1/1/2003
• "New Therapeutic Options in Indolent Lymphoma" 
  Fox Chase Cancer Center - 1/1/2003
• "Chronic Lymphocytic Leukemia" 
  Long Island College Hospital - 1/1/2002
• Medical Grand Rounds: "Melanoma" 
  Beth Israel Medical Center, NY - 1/1/2002
• Oncology Grand Rounds: "Lung Cancer: New Therapy Options" 
  Cabrini Medical Center, NY - 1/1/2002
• Oncology Grand Rounds: "Chronic Lymphocytic Leukemia" 
  St. Barnabas Hospital, Livingston, NJ - 1/1/2002
• "New Therapeutic Options in Indolent NHL" 
  Montefiore Medical Center, Bronx, NY - 1/1/2001
• Grand Rounds: "New Therapeutic Options for Indolent NHL" 
  University of Pennsylvania Cancer Center - 1/1/2000
• Medical Grand Rounds: "New Therapeutic Options for Indolent NHL" 
  Beth Israel Medical Center, NY - 1/1/2000
• "New Options for Therapy of Indolent Lymphoma" 
  State University of NY, Syracuse, NY - 1/1/1998
• "New Therapeutic Options for Indolent Lymphoma" 
  Georgetown University Medical Center, Washington, DC - 1/1/1998
• "Indolent NHL" 
  Lenox Hill Hospital, NY - 1/1/1998
• "New Therapeutic Options for Indolent NHL" 
  Staten Island University Hospita, NY - 1/1/1998
• Join now to see all

Other

• Empowering targeted therapy: Lessons from Rituximab. 
  Olszewki AJ, Grossbard ML, Science STKE (Electronic Resource)
  7/13/2004
• Malignant Lymphomas. Canada: BC Decker, Inc. (Editor) 
  Grossbard ML
  1/1/2001
• Dose-adjusted EPOCH chemotherapy and rituximab (R-EPOCH): An effective regimen in poor pognosis aggressive B-cell non-Hodgkin's lymphoma. 
  Gutierrez ME, Grossbard M, Jaffe E, Chabner BA, Wilson WH, Monographs in Lymphoma; Physicians Education Resource
  1/1/2000
• Monoclonal antibody treatment of non-Hodgkin's lymphoma: Current status and future prospects. 
  Grossbard ML, Multani PS, Monographs in Lymphoma, Physicians Education Resource
  1/1/1999
• Monoclonal Antibody Based Therapy of Cancer. New York: Marcel Dekker (Editor) 
  Grossbard ML
  1/1/1998
• Clinical simulations in the management of hematologic malignancies. 
  Grossbard ML, Medical Age Publishing
  Norwalk, CT - 1/1/1995
• Clinical simulations in the diagnosis and management of chronic lymphocytic leukemia. 
  Grossbard ML, Medical Age Publishing
  Norwalk, CT - 1/1/1993
• Join now to see all